290 related articles for article (PubMed ID: 28436001)
1. Gait instability in valproate-treated patients: Call to measure ammonia levels.
Kipervasser S; Elger CE; Korczyn AD; Nass RD; Quesada CM; Neufeld MY
Acta Neurol Scand; 2017 Nov; 136(5):401-406. PubMed ID: 28436001
[TBL] [Abstract][Full Text] [Related]
2. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
Hamed SA; Abdella MM
Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
[TBL] [Abstract][Full Text] [Related]
3. Differential ammonia decay kinetics indicates more than one concurrent etiological mechanism for symptomatic hyperammonemia caused by valproate overdose.
Mojumder DK; De Oleo RR
Indian J Pharmacol; 2014; 46(3):345-7. PubMed ID: 24987188
[TBL] [Abstract][Full Text] [Related]
4. Hyperammonemia following intravenous valproate loading.
DeWolfe JL; Knowlton RC; Beasley MT; Cofield S; Faught E; Limdi NA
Epilepsy Res; 2009 Jul; 85(1):65-71. PubMed ID: 19299111
[TBL] [Abstract][Full Text] [Related]
5. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
Tseng YL; Huang CR; Lin CH; Lu YT; Lu CH; Chen NC; Chang CC; Chang WN; Chuang YC
Medicine (Baltimore); 2014 Sep; 93(11):e66. PubMed ID: 25192484
[TBL] [Abstract][Full Text] [Related]
6. [Hyperammonemia in valproate therapy in children and adolescents].
Laub MC
Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
[TBL] [Abstract][Full Text] [Related]
7. Influence of valproate-induced hyperammonemia on treatment decision in an adult status epilepticus cohort.
Habhab SF; Ulvin LB; Taubøll E; Svalheim S; Olsen KB; Horn MA; Heuser K
Epilepsy Behav; 2020 Oct; 111():107193. PubMed ID: 32759060
[TBL] [Abstract][Full Text] [Related]
8. Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease).
Larsen EP; Ostergaard JR
Seizure; 2014 Jun; 23(6):429-34. PubMed ID: 24647346
[TBL] [Abstract][Full Text] [Related]
9. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
Yamada H; Shishido T; Mukai T; Araki M; Naka H; Tokinobu H
Rinsho Shinkeigaku; 2019 May; 59(5):258-263. PubMed ID: 31061301
[TBL] [Abstract][Full Text] [Related]
10. Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy.
Kwack DW; Kim DW
Clin Neurol Neurosurg; 2023 Oct; 233():107962. PubMed ID: 37717359
[TBL] [Abstract][Full Text] [Related]
11. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
[TBL] [Abstract][Full Text] [Related]
12. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
[TBL] [Abstract][Full Text] [Related]
13. Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure.
Panda S; Radhakrishnan K
J Assoc Physicians India; 2004 Sep; 52():746-8. PubMed ID: 15839456
[TBL] [Abstract][Full Text] [Related]
14. Valproate induced non hepatic hyperammonaemic encephalopathy (VNHE)--a study from tertiary care referral university hospital, north India.
Mehndiratta MM; Mehndiratta P; Phul P; Garg S
J Pak Med Assoc; 2008 Nov; 58(11):627-31. PubMed ID: 19024136
[TBL] [Abstract][Full Text] [Related]
15. [Hyperammonemic encephalopathy associated with valproate acid].
Osuna MT; Burcet J; Ramió L; Ustrell X; Silva Y; Molins A
Neurologia; 2003; 18(6):347-50. PubMed ID: 12838456
[TBL] [Abstract][Full Text] [Related]
16. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction.
Zaret BS; Beckner RR; Marini AM; Wagle W; Passarelli C
Neurology; 1982 Feb; 32(2):206-8. PubMed ID: 6798491
[TBL] [Abstract][Full Text] [Related]
17. Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy.
Vossler DG; Wilensky AJ; Cawthon DF; Kraemer DL; Ojemann LM; Caylor LM; Morgan JD
Epilepsia; 2002 Feb; 43(2):154-9. PubMed ID: 11903461
[TBL] [Abstract][Full Text] [Related]
18. Valproate (VPA)-associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012.
Cheng M; Tang X; Wen S; Yue J; Wang H
Compr Psychiatry; 2013 Jul; 54(5):562-7. PubMed ID: 23246073
[TBL] [Abstract][Full Text] [Related]
19. Incidence, Presentation, and Risk Factors for Sodium Valproate-Associated Hyperammonemia in Neurosurgical Patients: A Prospective, Observational Study.
Woo PYM; Woo AWY; Lam SW; Ko NMW; Ho JWK; Chu ACH; Kwan MCL; Chan Y; Wong HT; Chan KY
World Neurosurg; 2020 Dec; 144():e597-e604. PubMed ID: 32916358
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for hyperammonemia in pediatric patients with epilepsy.
Yamamoto Y; Takahashi Y; Imai K; Mishima N; Yazawa R; Inoue K; Itoh K; Kagawa Y; Inoue Y
Epilepsia; 2013 Jun; 54(6):983-9. PubMed ID: 23409971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
